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Introduction
Biologic Response modifiers (BRMs) are sparingly used in
the Indian subcontinent for two main reasons: economic
constraints and concern of infections. We have used
BRMs since 2006, albeit with stringent screening.There is
a dearth of detail re the use and safety of BRMs from this
part of the world. This study was undertaken to add to
the knowledge about the use of BRMs in children with
rheumatic diseases.
Objectives
1.To study the use of BRMs in a cohort of pediatric
rheumatic diseases2.To evaluate their safety over a long-
itudinal follow up.
Methods
Demographic, clinical and treatment details along with
the screening used and side effects, if any, were retro-
spectively collected on a predesigned proforma.
Results
Demographics: 105 children (61 boys) were given a BRM
(Jan’06-May’13). Median age at diagnosis of a rheumatic
ds. was 9.8 yrs (1.25-16.6 yrs) & median age at BRM com-
mencement 12 yrs (2.66-18 yrs). Median duration of fol-
low up after commencement of BRM was 29 mths (1-90
mths) Usage: Indications: JIA was the commonest diag-
nosis where BRM was used in 93(ERA:44, SJIA:29, poly:13,
Oligo:5), 7 had SLE, 2 had Kawasaki disease. There was 1
patient each of Takayasu, Sarcoidosis & Overlap syn-
drome. BRM used: Etanercept was the commonest &
used in 42 children, Infliximab in 35, Tocilizumab in 34,
Rituximab in 8 and Abatacept in 3.69 received one
BRM,16 were given 2 & 1 child received 3 BRMs consecu-
tively. Reasons: Use of BRMs for each ds: JIA: Polyarticu-
lar course unresponsive to Methotrexate & steroids: 43,
early hip involvement: 23; cervical spine ds.:7; Sacroiliitis
unresponsive to NSAIDs:5, midfoot ds:4, persistent sys-
temic features:7, uveitis:4, chr.MAS:1; secondary amy-
loid:1. SLE:Used in7; nephritis:5, hemolytic anemia:1 &
coronary artery vasculitis:1. Misc: 2 had Kawasaki disease
& 1 had Takayasu. Pre BRM Screening and results:
Screen:Included, Mantoux test, Q-gold, Chest X Ray, USG
abdomen, Contrast enhanced CT thorax, HIV,HbsAg &
HCV antibodies. Results: All were negative for HIV,
HbsAg & HCV antibodies·Chest X ray normal in104; 1
had previous endobronchialTB·Mantoux test positive in 4:
evaluation confirmed latent TB. BRM commenced after 8
weeks. Follow up: Considering the exorbitant cost and the
self paying nature for a majority of patients, BRMs were
used as remission inducing agents. Of a total of 105 chil-
dren, 93 had JIA: 56 discontinued BRMs of which 34
remained in clinical remission on DMARDs. 20 stopped
due to financial constraints, 7 did not respond to the
BRM, 5 had a BRM related adverse effect. Safety: There
were no serious adverse events. All children were premedi-
cated before infusion& monitored for hemodynamic stabi-
lity. 5 children had side effects for which BRM had to be
stopped (worsening of sarcoid rash in 1, new onset of vas-
culitic rash in 1, persistent neutropenia in 3). 8 children
had allergic rhinitis (during Tocilizumab). Dengue fever
was diagnosed in 2, Herpes zoster in 2, acute otitis media
in 1, acute parotitis in 1, and varicella in 1 on follow up. 2
children had a positive Mantoux after 1 yr of Infliximab
though did not have any evidence of TB on detailed
screening. There was no mortality in the cohort.
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Conclusion
BRMs can be safely used as remission inducing agents
in a country with a high rate of infectious diseases. Up
to 1/3 of cohort remained in clinical remission off
BRMs over a median follow up of 29 months. There
were no major adverse events.
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